New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 25, 2014
07:32 EDTVVUS, ACRXAcelRx appoints Timothy Morris as CFO
AcelRx Pharmaceuticals (ACRX) announced the appointment of Timothy E. Morris as CFO. Morris brings 30 years of professional finance and accounting experience to AcelRx, 18 of those years spent in the role of CFO, most recently operating in this capacity at VIVUS (VVUS). Morris will be responsible for managing the company's finance operations, its information systems and human resource and investor relations functions. Jim Welch, who had served as CFO since October 2010, departed the company to pursue other business opportunities.
News For ACRX;VVUS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
16:07 EDTVVUSVIVUS continues talks with U.S., EU over Qsymia
VIVUS announced an operational update, including certain key corporate decisions and plans regarding Qsymia capsules CIV. These plans include further investments in high-value, consumer-focused digital media projects in support of obesity education and Qsymia, and focusing the Qsymia field sales organization of approximately 100 territories on the most productive target areas. Management will continue discussions with U.S. and EU regulatory authorities regarding Qsymia development and potential cost-saving measures related to the planned cardiovascular outcomes trial, or CVOT, and will aim to further improve corporate efficiency and control costs while maintaining and extending the value of avanafil. VIVUS plans to discuss with U.S. regulatory authorities and key consultants potential cost-saving alternatives with respect to the Qsymia CVOT, known as AQCLAIM. The company is also in the process of pursuing approval for Qsymia in the EU and other key countries, as well as new indications in other chronic diseases such as obstructive sleep apnea, or OSA, and type 2 diabetes. VIVUS plans to optimize spending while pursuing these potential objectives.
March 20, 2015
15:04 EDTACRXAcelRx to reduce workforce by approximately 36%
Subscribe for More Information
15:02 EDTACRXAcelRx names Howard Rosen as interim CEO
AcelRx Pharmaceuticals (ACRX) announced the appointment of Howard Rosen as interim CEO of AcelRx, effective April 1. Rosen is a technically trained executive with over 25 years of success growing start-up and mid-size biopharmaceutical companies. Rosen previously held senior-level general management positions and functional roles in strategy, marketing, finance, business development, and research and development at Gilead Sciences (GILD) and ALZA Corporation. Rosen has served on the Board of Directors of AcelRx since 2008 and currently serves on the Board of Directors of Alcobra and several private biopharmaceutical companies.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use